Huadong Med's UK unit invests in Kylane, takes global rights to medical cosmetic products

China-based Huadong Medicine Co., Ltd (000963.SZ) announced that its UK unit Sinclair Pharma Ltd has entered into an equity investment and licensing agreement with Swiss medical cosmetics firm Kylane Laboratoires SA. Per the agreement, Sinclair will acquire a 20% stake in Kylane for EUR 6 million (USD 7 million) and be awarded one seat on Kylane's board. Sinclair will also take exclusive global rights to the latter’s two key products in the facial and body filler fields for an undisclosed amount of development fees and other monies. In addition, Sinclair retains priority negotiation rights to Kylane ‘s other products in future.

Huadong previously struck a licensing deal with Kylane in Q1 2020, according to the announcement, obtaining exclusive global rights to the latter’s MaiLiseries hyaluronic acid products. CE certificate was secured in June this year, with marketing expected next year in the EU. China is expected to be the largest medical cosmetic services market by 2021, citing Frost & Sullivan, and is forecast to be generating RMB 360.1 billion (around USD 53 billion currently) in market sales by 2023.


Related news
Ireland-based Allergan announced the commercial launch of its Juvéderm VOLIFT with Lidocaine in the Bo’Ao Medical Tourism Pilot Zone of Hainan province.
Austria-based medical aesthetics firm Croma-Pharma GmbH announced plans to establish a joint venture (JV) in China via a partnership with China National Biotech Group (CNBG), an affiliate of China National Pharmaceutical Group Corp., (Sinopharm; HKEX.01099).
China’s National Medical Products Administration (NMPA) released notice of medical devices awarded market approval during April 2020.
Ireland-based Allergan announced market approval from the National Medical Products Administration (NMPA) for its hyaluronic acid gel filler Volift.
Japan-based firms Eisai Co., Ltd (TSE.4523) and Seikagaku Corporation announced a partnership agreement in relation to the latter’s diclofenac conjugated sodium hyaluronate SI-613, an osteoarthritis drug.
Recent news
Mexican authorities last week revealed that the SARS-CoV-2 vaccine advanced purchases that were announced recently will include 51 million doses from the World Health Organization (WHO)’s COVAX initiative, up to 34 million of Pfizer’s double-dose immunization, 77 million of AstraZeneca (AZ)’s double-dose vaccine, and 35 million of CanSino’s single-dose treatment, totalling 197 million doses for 116.7 million people.
According to GBI analysis, Chile's Institute of Public Health (ISP) this week published the approvals of US firm Pfizer’s biosimilar Ruxience (rituximab), Netherlands-based Synthon’s Gatrel (sunitinib), a first-in-market generic version of Pfizer’s Sutent, as well as Argentina-based Varifarma’s Nibclus (ponatinib), a first-mover generic of Pint Pharma’s Iclusig.
Brazil’s Ministry of Science, Technology, Innovation and Communication (MCTIC) this week announced results of a clinical trial (CT) evaluating the efficacy of broad-range antiviral nitazoxanide against early-stage COVID-19.
Óscar Vicente Scavone, president of Paraguay-based Laboratorios Éticos, last week commented on the local pharmaceutical industry’s situation and prospects amid the COVID-19 pandemic.
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA:600196; HKG:02196) announced clinical trial approval from the US FDA for ORIN1001, a potential first-in-class treatment for idiopathic pulmonary fibrosis (IPF).
Chinese internet giant Tencent (HK.00700) trumpeted the launch of two new products in the healthcare space.
Russian bank and financial services giant Sberbank and compatriot pharma firm JSC Pharmasyntez signed a cooperation agreement on October 14, 2020.
Analytics Snapshot

Analytics Snapshot